FDA Releases Guidance on Drugs for Treatment of Opioid Use Disorder

News
Article

The guidance discusses acceptable clinical endpoints for demonstrating effectiveness of drugs developed to treat opioid use disorder.

FDA published guidance on October 1, 2020 directed at sponsors developing drugs to treat opioid use disorder (OUD). The guidance discusses acceptable clinical endpoints for demonstrating effectiveness of OUD treatments but does not address the development of drugs that only provide relief of opioid withdrawal symptoms.

Specifically, the guidance encourages the evaluation of the reduction of adverse outcomes related to OUD such as mortality, need for emergency medical interventions, and hepatitis C infection. The guidance also discusses other endpoints such as change in disease status using diagnostic criteria for OUD, change in drug use pattern, and patient-reported outcomes.

The guidance also stresses the importance of benefit-risk considerations. “If a product is associated with a risk of serious adverse events, more compelling demonstrations of clinical benefit may be needed to outweigh this risk. If the product itself has abuse potential, FDA will consider the positive and negative public health effects of the drug, including risk of diversion, the drug’s potential effect on risks to both patients and nonpatients, such as members of the patient’s household (e.g., children, teenagers, visitors, and others). The risks considered include those related to misuse, abuse, OUD, overdose, and accidental exposures, particularly in children,” FDA states in the guidance.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes